You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 61 No. 12, December 2004 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Contribution
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on ISI (19)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Alzheimer Disease
 •Lewy Body Disease
 •Alert me on articles by topic

Lewy Bodies in the Amygdala

Increase of {alpha}-Synuclein Aggregates in Neurodegenerative Diseases With Tau-Based Inclusions

Anca Popescu, MD; Carol F. Lippa, MD; Virginia M.-Y. Lee, PhD; John Q. Trojanowski, MD, PhD

Arch Neurol. 2004;61:1915-1919.

Background  Increased attention has been given to {alpha}-synuclein aggregation in nonsynucleinopathies because {alpha}-synuclein–containing Lewy bodies (LBs) influence symptoms. However, the spectrum of disorders in which secondary inclusions are likely to occur has not been defined. Amygdala neurons commonly develop large numbers of secondary LBs, making it a practical region for studying this phenomenon.

Objective  To characterize the spectrum of diseases associated with LB formation in the amygdala of neurodegenerative disease and control cases.

Design  An autopsy series of 101 neurodegenerative disease and 34 aged control cases. Using immunohistochemistry studies, we examined the amygdala for {alpha}-synuclein aggregates.

Results  Lewy bodies were often abundant in classic Pick disease, argyrophilic grain disease, Alzheimer disease, and dementia with LBs but not in cases with amygdala degeneration lacking tau-based inclusions, control cases, preclinical disease carriers, or degenerative diseases lacking pathologic involvement of the amygdala. The exposed {alpha}-synuclein epitopes were similar in all cases containing LBs.

Conclusions  Abnormal {alpha}-synuclein aggregation in the amygdala is disease selective, but not restricted to disorders of {alpha}-synuclein and {beta}-amyloid. Our data are compatible with the notion that tau aggregates predispose neurons to develop secondary LBs.


Author Affiliations: Department of Neurology, Drexel University College of Medicine (Drs Popescu and Lippa), and Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine (Drs Lee and Trojanowski), Philadelphia.







HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2004 American Medical Association. All Rights Reserved.